Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors (Q33967714)

30 July 2017

Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors (English)

1 reference

30 July 2017

1 reference

Sun L

1

1 reference

PubMed ID

10893547

30 July 2017

McMahon G

series ordinal

2

1 reference

30 July 2017

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

5

1 reference

30 July 2017

8

1 reference

30 July 2017

344-353

1 reference

Tumor angiogenesis: therapeutic implications

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Tumor dormancy in vivo by prevention of neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Current approaches to targeting cancer using antiangiogenesis therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

The rationale and future potential of angiogenesis inhibitors in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Inhibition of malignant angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Specificity of vascular endothelial cell growth factor receptor ligand binding domains

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Protein tyrosine kinase inhibitors as novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

American Association for Cancer Research 1997: progress and new hope in the fight against cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Three-dimensional structure of the tyrosine kinase c-Src

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Crystal structure of the Src family tyrosine kinase Hck

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2800%2901534-8

7 January 2021

10.1016/S1359-6446(00)01534-8

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10893547